JCJoel O. Cresser-Brown

Joel O. Cresser-Brown

*This is an algorithmically generated author record based on publicly available information.

Joel O. Cresser-Brown has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    BromoCatch: a self-labelling tag platform for protein analysis and live cell imaging

    by Maria Rodriguez-Rios, Conner G. Craigon, Mark A. Nakasone, Adam G. Bond, Mark Dorward, Anthony K. Edmonds, Mark C. Norley, Robert E. Arnold, Paul M. Wood, Stephen J. Reynolds, et al.

    Visualizing and manipulating proteins in live cells is crucial for studying complex biological processes. Self-labelling protein (SLP) tags such as HaloTag and SNAP-tag can be fused to genes of interest to allow protein labelling in cells. Limitations including size of the tag and suboptimal fitness of reactivity motivate development of improved tools to enable rapid, specific and stable protein labelling. We present BromoCatch, a novel SLP platform based on a small ∼13 kDa bromodomain (BD) engineered with a nucleophilic cysteine for covalent ligand engagement. A structure-based designed library of 16 “bumped” binders bearing diverse electrophilic warheads was screened against two different cysteine mutants using differential scanning fluorimetry and intact protein mass spectrometry to monitor covalent complex formation. The para-acrylamide bumped derivative MR116 and the Brd4-BD2 double mutant L387A,E438C formed the most potent and stable adduct, and its binding mode through covalent modification was confirmed by an X-ray cocrystal structure solved to 1.3 Å of resolution. BromoCatch exhibited potent and irreversible target engagement in cells through nanoBRET and residence time assays. Practicality and scope are further demonstrated through the design and proof-of-concept application of a biotinylated conjugate, PROTAC tag degraders, and fluorescent probes of both full-on and switch-on types for ex-cellulo and live-cell imaging. Together, we qualify BromoCatch as a novel, versatile and efficient protein labelling tool and technology platform. Its advantageous design features and kinetic fitness, and its modular design enabling diverse functionalities, are anticipated to usher a range of future applications and witness broad utility.


  • Open Access

    Development of p300-targeting degraders with enhanced selectivity and onset of degradation

    by Graham P. Marsh, Mark S. Cooper, Sean Goggins, Stephen J. Reynolds, Dean F. Wheeler, Joel O. Cresser-Brown, Robert E. Arnold, Emily G. Babcock, Gareth Hughes, Darko Bosnakovski, et al.

    P300 and CBP are paralogous epigenetic regulators and promising therapeutic targets for which TPD offers the potential to achieve paralog-selective degradation.


  • Efficient, multi-hundred-gram scale access to E3 ubiquitin ligase ligands for degrader development

    by Mark S. Cooper, Mark C. Norley, Simon Armitage, Joel O. Cresser-Brown, Anthony K. Edmonds, Sean Goggins, Jonathan P. Hopewell, Burhan Karadogan, Kevin A. Knights, Toby J. Nash, et al.

    Supporting degrader discovery programs in scale and scope: facile access to multi-hundred-gram quantities of the common E3 ligase ligands.